Why Heron Therapeutics, Inc. (HRTX) Price Target Was Reduced to $4 at H.C. Wainwright?
H.C. Wainwright analyst Brandon Folkes reduced Heron Therapeutics, Inc.'s (HRTX) price target to $4 from $6, reiterating a Buy rating, following weaker-than-expected first-quarter performance and uncertainty regarding the Zynrelef product's growth. The company reported $34.7 million in Q1 2026 net revenue, with acute care revenue up 32% year-over-year, and reaffirmed full-year 2026 revenue guidance of $173–183 million. Despite product growth, the analyst emphasized the need for better revenue conversion and commercial momentum to sustain investor interest.
Heron Therapeutics (HRTX) price target decreased by 15.38% to 3.74
The article reports that the price target for Heron Therapeutics (HRTX) has been reduced by 15.38%, bringing it down to $3.74. This adjustment reflects a significant change in the financial outlook for the company based on analyst expectations.
Heron Therapeutics (HRTX) price target decreased by 15.38% to 3.74
Heron Therapeutics (HRTX) recently experienced a price target decrease of 15.38%, bringing it down to $3.74. This adjustment could reflect updated analyst expectations regarding the company's future performance or market conditions.
Heron outlines $173M-$183M 2026 net product sales outlook as it targets return to positive adjusted EBITDA
Heron Therapeutics provided a financial outlook for 2026, projecting net product sales between $173 million and $183 million. The company aims to achieve positive adjusted EBITDA during the same period, focusing on its commercial portfolio and pipeline products.
Heron Therapeutics (HRTX) Quarterly Loss Revives Dilution Fears And Tests Profitability Narrative
Heron Therapeutics (HRTX) reported a Q1 2026 loss of US$8.1 million and a basic EPS loss of US$0.04, renewing dilution concerns despite revenue of US$34.7 million. The company's trailing twelve-month net loss stands at US$30.9 million, fueling debates between bearish investors worried about ongoing cash burn and the need for external financing, and bullish analysts who foresee significant earnings growth and a shift to profitability within three years. This quarterly performance tests the narrative of future profitability against current financial realities and modest revenue growth.
Adage Capital amendment shows 0% ownership in Heron Therapeutics (HRTX)
Adage Capital Management, along with Robert Atchinson and Phillip Gross, filed an amended Schedule 13G/A, reporting 0% beneficial ownership of Heron Therapeutics (HRTX) common stock as of March 31, 2026. The filing indicates no voting or dispositive power over any HRTX shares for the reporting persons. This is considered a routine administrative amendment, as the reported ownership is below the 5% threshold.
H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $4
H.C. Wainwright has reiterated its Buy rating for Heron Therapeutics (HRTX.US) and maintained its price target of $4. This indicates the firm's continued positive outlook on the company's stock performance.
Acute-care net revenue up 32% as Heron settles CINVANTI patent case
Heron Therapeutics reported Q1 2026 net revenue of $34.7 million, a 10.8% decrease year-over-year, but reaffirmed its full-year guidance for 2026. The Acute Care franchise saw strong growth with revenue up 32%, driven by ZYNRELEF and APONVIE, while Oncology Supportive Care revenue declined. The company also announced a settlement in the CINVANTI patent litigation with Baxter Healthcare.
Heron Therapeutics Inc (HRTX) Q1 2026 Earnings Call Highlights: Resilient Growth Amidst Challenges By GuruFocus
Heron Therapeutics Inc (HRTX) reported Q1 2026 net sales of $34.7 million, with acute care revenue growing 32% year-over-year despite challenges from severe weather. While gross margin was below typical levels and adjusted EBITDA was negative, the company maintained market share in oncology and provided a positive outlook for 2026 net product sales and adjusted EBITDA. Key growth drivers include the successful IGNITE program for ZYNRELEF and the pending expansion of its sales force.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2026 Earnings Call Transcript
Heron Therapeutics (NASDAQ:HRTX) reported its Q1 2026 earnings, missing EPS expectations at $-0.04 against an anticipated $-0.03, partially due to severe weather in January affecting elective surgeries. Despite seasonal headwinds and temporary gross margin pressure from a secondary supplier, the company reaffirmed its 2026 guidance, expecting net product sales between $173 million and $183 million and adjusted EBITDA of $10 million to $20 million, driven by strong growth in its Acute Care portfolio and strategic sales force expansion. Key growth drivers include the IGNITE program for ZYNRELEF and the inclusion of APONVIE in new consensus guidelines for postoperative nausea and vomiting.
Needham Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $3
Needham has reiterated its Buy rating for Heron Therapeutics (HRTX.US), indicating continued confidence in the company. The firm has also maintained its target price for HRTX.US at $3. This suggests Needham believes the stock has potential to reach this valuation.
Heron Therapeutics (NasdaqCM:HRTX) Stock Forecast & Analyst Predictions
Heron Therapeutics is forecast to grow earnings by 58.9% and revenue by 13.9% per annum, though analysts no longer expect the company to break even in the foreseeable future, predicting a net loss of US$39.7m in 2028. Recent Q1 2026 earnings missed analyst expectations, and the company's share price has shown volatility, dropping 35% over the past year. Analysts have also reduced price targets to an average of US$4.33, indicating caution despite the potential for future upside from revised profit outlook and discount rates.
Needham Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $3
Needham has reiterated its Buy rating for Heron Therapeutics (HRTX.US) and maintained its target price at $3. This indicates a continued positive outlook on the company's stock performance from the analyst firm.
Heron Therapeutics (NASDAQ:HRTX) Releases Earnings Results, Misses Expectations By $0.01 EPS
Heron Therapeutics (NASDAQ:HRTX) announced its Q1 earnings, reporting an EPS of -$0.04, missing analyst expectations by $0.01, and revenue of $34.71 million, below the estimated $36.72 million. Despite the miss, the company saw strong demand for its acute care products, ZYNRELEF and APONVIE, and reaffirmed its full-year 2026 sales and adjusted EBITDA guidance. The stock traded down 23.1% following the announcement.
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
Heron Therapeutics (Nasdaq: HRTX) announced its Q1 2026 financial results, reporting total net revenue of $34.7 million and reaffirming full-year 2026 guidance of $173–$183 million net revenue and $10–$20 million Adjusted EBITDA. The company saw strong year-over-year growth in its Acute Care franchise, driven by ZYNRELEF® and APONVIE®, and settled patent litigation with Baxter Healthcare Corporation involving CINVANTI®. Heron continues to expand its commercial efforts and advance its ZYNRELEF prefilled syringe lifecycle program.
Heron Therapeutics Backs 2026 Rev $173M-$183M >HRTX
Heron Therapeutics expects revenue between $173 million and $183 million in 2026. The article also mentions Unity Software's fourth-quarter financial results, with revenue increasing 35% year-over-year to $609 million, beating estimates, despite reporting a quarterly loss of 66 cents per share. This financial update provides key figures for both Heron Therapeutics and Unity Software investors.
HERON THERAPEUTICS, INC. /DE/ 1Q 2026: Revenue $34.7M, EPS $(0.04) — 10-Q Summary
Heron Therapeutics reported its first-quarter 2026 financial results, showing revenue of $34.7 million and a diluted loss per share of $(0.04). This represents a decrease in revenue and a swing from net income to a net loss compared to the same quarter last year. Despite the overall decline, acute care sales increased, driven by growth in ZYNRELEF and APONVIE, both of which gained significant reimbursement and clinical adoption milestones.
[8-K] HERON THERAPEUTICS, INC. /DE/ Reports Material Event
Heron Therapeutics (HRTX) reported Q1 2026 net revenue of $34.7 million, a 10.8% year-over-year decrease, with a net loss of $8.1 million. Despite a decline in the Oncology Supportive Care franchise, the Acute Care franchise, featuring ZYNRELEF and APONVIE, grew by 32%. The company reaffirmed its full-year 2026 guidance for net revenue of $173–$183 million and Adjusted EBITDA of $10–$20 million.
Heron Therapeutics Announces First Quarter 2026 Financial Results and Reaffirms Guidance
Heron Therapeutics announced its Q1 2026 financial results, reporting total net revenue of $34.7 million and strong year-over-year growth in its Acute Care franchise (+32%). The company reaffirmed its full-year 2026 net revenue guidance of $173–$183 million and Adjusted EBITDA of $10–$20 million. Key product highlights include continued demand growth for ZYNRELEF® and APONVIE®, and a settlement reached in CINVANTI® patent litigation.
Heron Therapeutics: Q1 Earnings Snapshot
Heron Therapeutics Inc. (HRTX) reported a first-quarter loss of $8.1 million, or 4 cents per share. The pharmaceutical company generated $34.7 million in revenue for the period and anticipates full-year revenue to be between $173 million and $183 million. This information is based on data from Zacks Investment Research.
Heron Therapeutics: Q1 Earnings Snapshot
Heron Therapeutics Inc. (HRTX) reported a first-quarter loss of $8.1 million, or 4 cents per share. The pharmaceutical company generated $34.7 million in revenue during the period, and anticipates full-year revenue to be between $173 million and $183 million. This financial update was generated by Automated Insights using Zacks Investment Research data.
Heron Therapeutics Q1 2026 earnings preview
This article is a placeholder for a Q1 2026 earnings preview for Heron Therapeutics. Currently, it contains no substantive content beyond the title.
Heron Therapeutics (HRTX) COO acquires 125,000 shares via RSU exercise
Heron Therapeutics' Chief Operating Officer, Mark Earl Hensley, exercised derivative securities to acquire 125,000 shares of common stock on May 6, 2026, as a result of restricted stock unit (RSU) settlement. This transaction was not a cash purchase and increased his direct holdings to 136,770 common shares. Hensley also retains 375,000 RSUs, which vest over time, starting with 25% on the first anniversary of the May 6, 2025 grant date.
Heron Therapeutics (HRTX) COO gains 11,770 shares through RSU conversion
Heron Therapeutics' Chief Operating Officer, Mark Earl Hensley, acquired 11,770 shares of common stock through the automatic conversion of Restricted Stock Units (RSUs) on April 30, 2026. This transaction increased his direct holdings of common shares to 11,770, with 176,545 RSUs remaining. The RSUs were granted on January 30, 2026, and are set to vest in 16 equal quarterly installments.
Heron EVP exercises RSUs into 23,464 common shares | HRTX Insider Trading
Heron Therapeutics EVP and Chief Development Officer William P. Forbes exercised 23,464 restricted stock units (RSUs) into common shares on April 30, 2026. This transaction was part of a routine RSU vesting and exercise, increasing his direct ownership to 209,111 common shares. Following this, he still holds 128,638 RSUs, which vest in quarterly installments.
[Form 4] HERON THERAPEUTICS, INC. /DE/ Insider Trading Activity
Heron Therapeutics EVP and CFO Ira Duarte exercised restricted stock units (RSUs) into common shares on April 30, 2026, totaling 25,229 shares through two transactions. These compensation-related exercises did not involve open-market sales. The RSUs are part of an ongoing equity compensation program, with 216,562 RSUs granted in January 2026 vesting in 16 equal quarterly installments.
Heron Therapeutics (NASDAQ: HRTX) CEO converts 84,810 RSUs to shares
Heron Therapeutics CEO Craig A. Collard recently converted 84,810 Restricted Stock Units (RSUs) into common stock through compensation-related transactions. This included acquiring 50,021 and 34,789 shares from RSU conversions, alongside 11,023 shares obtained via the company's Employee Stock Purchase Plan. The transactions, stemming from previously granted equity awards that vest over time, highlight Collard's increasing stake in the company.
Analysts Estimate Heron Therapeutics (HRTX) to Report a Decline in Earnings: What to Look Out for
Analysts are forecasting a year-over-year decline in earnings and revenues for Heron Therapeutics (HRTX) for the quarter ended March 2026. The company is expected to report a quarterly loss of $0.03 per share, a 400% decrease from the prior year, with revenues down 7.1% to $36.13 million. The Zacks Earnings ESP indicates a potential earnings miss for HRTX, while an industry peer, Zoetis (ZTS), is expected to beat earnings estimates.
[ARS] HERON THERAPEUTICS, INC. /DE/ SEC Filing
This article announces an ARS SEC filing by HERON THERAPEUTICS, INC. (HRTX) on April 30, 2026, with a low impact and neutral sentiment. It provides links to view the full PDF document and the original filing on SEC EDGAR. The page also includes an overview of HRTX's stock data, recent news, and other SEC filings.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Receives Average Recommendation of "Hold" from Brokerages
Heron Therapeutics, Inc. (NASDAQ:HRTX) has received a consensus "Hold" recommendation from brokerages, with an average 1-year price target of $4.50. The company recently surpassed quarterly earnings and revenue estimates, reporting EPS of ($0.02) against an expected ($0.03) and revenue of $40.59 million, exceeding the $39.53 million consensus. Institutional ownership is high at 80.01%, with significant position increases by firms like Goldman Sachs and JPMorgan.
Heron Therapeutics outlines $173M–$183M 2026 sales targets amid acute care momentum and expanded commercial investment
Heron Therapeutics has set sales targets of $173M–$183M for 2026, driven by momentum in its acute care segment. The company plans to expand its commercial investment to achieve these goals and capitalize on opportunities within the acute care market. This strategic outlook highlights Heron's focus on growth and market presence in the coming years.
Heron sets May 11 webcast for Q1 results and business updates
Heron Therapeutics (Nasdaq: HRTX) announced it will report its first-quarter 2026 financial results and discuss business highlights on Monday, May 11, 2026, at 8:30 a.m. ET. The event will include a conference call and live webcast accessible through registration on the company's investor relations website, where an archive will also be available for 60 days. Investors are advised to register and dial in 15 minutes early to avoid delays.
Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026
Heron Therapeutics announced it will report its first quarter 2026 financial results on Monday, May 11, 2026, through a conference call and live webcast. The event, scheduled for 8:30 a.m. ET, will also cover recent business highlights. Interested parties can access dial-in details via a registration link or the Investor Relations section of the company's website.
Heron Therapeutics outlines $173M–$183M 2026 sales targets amid acute care momentum and expanded commercial investment
Heron Therapeutics has announced ambitious sales targets for 2026, aiming for $173 million to $183 million, largely driven by its acute care portfolio including Zynrelef. The company plans to significantly increase its commercial investment, particularly by doubling its Zynrelef sales force. This strategic move is expected to leverage market demand and expand the product's reach within the acute care setting.
Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026
Heron Therapeutics announced it will host a conference call and live webcast on Monday, May 11, 2026, at 8:30 a.m. ET to discuss its first quarter 2026 financial results and recent business highlights. Interested parties can access the call via a registration link or through a webcast on the company's investor relations website. An archive of the event will be available for 60 days following the call.
HRTX Edges Higher As Insider Ownership Change Draws Attention
Heron Therapeutics Inc. (HRTX) stocks increased by 19.98% following positive sentiment regarding new drug developments and a reported change in beneficial ownership by an insider. While insider activity isn't a direct catalyst, it signals active engagement, especially as the stock experienced a short-term momentum pop from $1.02 to $1.20. Despite this, HRTX remains a commercially active biotech company with improving but delicate fundamentals, marked by high leverage and negative profitability, making it a high-beta trade for short-term traders.
H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $6
H.C. Wainwright has reiterated its Buy rating for Heron Therapeutics (HRTX.US) and maintained a target price of $6.00. This continued positive outlook suggests the firm sees strong potential in the pharmaceutical company.
[Form 4] HERON THERAPEUTICS, INC. /DE/ Insider Trading Activity
William P. Forbes, EVP and Chief Development Officer at Heron Therapeutics, Inc. (HRTX), exercised 3,874 restricted stock units (RSUs) into common shares on April 19, 2026. This transaction was compensation-related, with a stated price of $0.00 per share, indicating vesting rather than a purchase. Following this, Forbes directly holds 185,647 shares of common stock and 27,120 restricted stock units, which vest in quarterly installments.
Heron Therapeutics files $125M mixed securities shelf
Heron Therapeutics has filed a mixed securities shelf worth $125 million. This filing allows the company to offer various types of securities, such as common stock, preferred stock, debt securities, and warrants, providing flexibility for future financing needs.
[Form 4] HERON THERAPEUTICS, INC. /DE/ Insider Trading Activity
This article details an insider trading activity for Heron Therapeutics, Inc. (HRTX), specifically focusing on EVP and CFO Ira Duarte. Duarte exercised restricted stock units, converting 3,874 units into common shares, and now directly holds 215,876 common shares and 27,120 restricted stock units. The report also highlights additional shares acquired through an Employee Stock Purchase Plan.
EBITDA per share of Heron Therapeutics Inc – LSE:0J4V
This article provides financial information for Heron Therapeutics Inc (LSE:0J4V), specifically highlighting its EBITDA per share. The content appears to be a data point from a financial charting platform, indicating the value and change over different periods. It is contextualized within the broader suite of tools and services offered by TradingView.
Heron Therapeutics (NASDAQ: HRTX) revises executive severance and CIC
Heron Therapeutics has revised the employment and retention agreements for its senior leadership, including CEO Craig Collard and other key executives. The amendments enhance severance protections, particularly during change-in-control scenarios, by increasing cash payments, accelerating equity vesting, and extending health coverage benefits. The company also updated bonus mechanics, restrictive covenants, and adopted North Carolina as the governing law.
Heron Therapeutics (HRTX) CEO exercises 62,500 RSUs into common stock
Heron Therapeutics (HRTX) CEO Craig A. Collard exercised 62,500 restricted stock units (RSUs) into an equal number of common stock shares at a $0.0000 exercise price. Following this transaction, Collard directly owns 648,255 shares of Heron Therapeutics common stock, which includes 14,045 shares acquired through an Employee Stock Purchase Plan. The RSUs vest in four equal annual installments, contingent on continued service.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Given Average Recommendation of "Hold" by Analysts
Heron Therapeutics (NASDAQ:HRTX) has received an average "Hold" recommendation from analysts, with one analyst rating it a sell, one a hold, and three a buy, leading to an average 12-month price target of $4.50. The company recently surpassed earnings and revenue expectations, reporting an EPS of ($0.02) against an expected ($0.03) and revenue of $40.6 million against $39.5 million. Institutional investors hold approximately 80% of the stock, with several firms modifying their positions and making substantial purchases in the fourth quarter.
Vanguard realigns holdings; Heron Therapeutics (HRTX) ownership shown as 0
The Vanguard Group filed an amendment to its Schedule 13G/A, disclosing 0 beneficially owned shares of Heron Therapeutics Inc. common stock, representing 0% of the class. This change is due to an internal realignment on January 12, 2026, where certain Vanguard subsidiaries/divisions now report separately in reliance on SEC Release No. 34-39538. The filing was signed by Ashley Grim, Head of Global Fund Administration, on March 27, 2026.
What is Northland Securities' Estimate for HRTX Q3 Earnings?
Northland Securities has revised its Q3 2026 EPS estimate for Heron Therapeutics (NASDAQ:HRTX) upward to $0.00, from a previous forecast of ($0.01), and projects Q4 2026 EPS of $0.01. The consensus full-year earnings estimate for Heron Therapeutics is ($0.13) per share, and the company recently reported Q4 EPS of ($0.02), surpassing consensus by $0.01 with revenues of $40.59 million.
If You Invested $1,000 in Heron Therapeutics Inc (HRTX)
This article analyzes the historical performance of Heron Therapeutics Inc (HRTX) stock, illustrating what a $1,000 investment would be worth over 1, 5, and 10 years, showing significant losses. It details the company's business as a commercial-stage biotechnology firm focused on acute care and oncology supportive care products like ZYNRELEF, APONVIE, CINVANTI, and SUSTOL. The piece also provides a year-by-year return comparison of HRTX against the S&P 500, showing substantial underperformance.
Baker BROS. Advisors LP Purchases New Position in Heron Therapeutics, Inc. $HRTX
Baker BROS. Advisors LP initiated a new position in Heron Therapeutics (NASDAQ:HRTX) during the third quarter, acquiring over 4.25 million shares valued at approximately $5.36 million. Heron Therapeutics recently reported better-than-expected quarterly earnings, with an EPS of -$0.02 and revenue of $40.59 million. Despite mixed analyst ratings (three Buys, two Sells, resulting in an average Hold) and a consensus price target of $4.50, institutional investors hold a significant 80% stake in the company.
Heron Therapeutics Inc (NASDAQ:HRTX) Reports Q4 2025 Revenue Beat and Positive 2026 Outlook
Heron Therapeutics Inc (NASDAQ:HRTX) reported a Q4 2025 revenue beat and issued a positive 2026 outlook, leading to a significant pre-market stock increase. The company's Acute Care franchise, featuring ZYNRELEF and APONVIE, demonstrated strong growth and is now the primary revenue driver. Despite a slight miss on EPS, investors are reacting positively to the robust revenue growth and especially the inaugural 2026 Adjusted EBITDA guidance of $10 to $20 million, signaling a move towards operational profitability.
Heron Therapeutics, Inc. (NASDAQ:HRTX) Given Average Recommendation of "Hold" by Brokerages
Heron Therapeutics (NASDAQ:HRTX) has received an average recommendation of "Hold" from five brokerages, with two analysts rating it a "sell" and three a "buy." The average 12-month price target is $4.50. Despite remaining unprofitable with a P/E of -7.44, the company slightly exceeded Q4 2025 earnings and revenue estimates.
